Back
CT.gov ↗CT.gov ↗CT.gov ↗CT.gov ↗
BEAM
Beam Therapeutics Inc.
Beam Therapeutics Inc. is a clinical-stage genetic medicine company developing precision gene editing therapies using base editing technology to treat serious diseases across multiple therapeutic areas. The company's approach focuses on making targeted, permanent changes to DNA to address the underlying genetic causes of disease, with lead programs in development for conditions including sickle cell disease and beta-thalassemia. Beam's base editing platform represents an advancement in gene therapy aimed at providing curative treatment options for patients with severe genetic disorders.
$30.33+52.18%1Y
BEAM · daily close · illustrative · 0 catalysts marked
Pipeline
Phase 2Sickle Cell Disease
Phase 2Lymphoblastic Lymphoma
Phase 2T-Cell Lymphoblastic Leukemia/Lymphoma
Phase 2Lymphoblastic Leukemia
Phase 2Glycogen Storage Disease Type Ia
Phase 2Alpha 1-Antitrypsin Deficiency
Catalyst Calendar
DEC
ReadoutBEAM-201
“A Phase 1/2, Dose-Exploration and Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited, Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) — primary completion 2026-12”
DEC
ReadoutBEAM-301: Single dose of BEAM-301 administered by IV
“A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa) Homozygous or Compound Heterozygous for the G6PC1 c.247C>T (p.R83C) Variant — primary completion 2027-12-30”
FEB
ReadoutBEAM-101
“A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients With Sickle Cell Disease and Severe Vaso-Occlusive Crises (Beacon Trial) — primary completion 2028-02”
MAY
ReadoutBEAM-302
“A Phase 1/2 Dose-exploration and Dose-expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease — primary completion 2028-05”